BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 32472023)

  • 1. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus.
    Jin X; Xu Q; Pu C; Zhu K; Lu C; Jiang Y; Xiao L; Han Y; Lu L
    Cell Mol Immunol; 2021 Aug; 18(8):1896-1903. PubMed ID: 32472023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
    Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
    Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.
    Dingfelder J; Aigner M; Taubmann J; Minopoulou I; Park S; Kaplan CD; Cheng JK; Van Blarcom T; Schett G; Mackensen A; Lutzny-Geier G
    Transplant Cell Ther; 2024 Jun; 30(6):582.e1-582.e10. PubMed ID: 38548226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment.
    Kambayana G; Surya Rini S
    Curr Rheumatol Rev; 2023 Jun; 19(3):260-269. PubMed ID: 36786138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-ANX A1 Antibody Therapy in MRL/lpr Murine Model of Systemic Lupus Erythematosus.
    Bradyanova S; Mihaylova N; Chipinski P; Manassiev Y; Herbáth M; Kyurkchiev D; Prechl J; Tchorbanov AI
    Arch Immunol Ther Exp (Warsz); 2021 Jul; 69(1):19. PubMed ID: 34322760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus.
    Liu L; Takeda K; Akkoyunlu M
    Front Immunol; 2020; 11():1569. PubMed ID: 32849532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
    Luo J; Niu X; Liu H; Zhang M; Chen M; Deng S
    Mol Immunol; 2013 Dec; 56(4):574-82. PubMed ID: 23911415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
    Mackensen A; Müller F; Mougiakakos D; Böltz S; Wilhelm A; Aigner M; Völkl S; Simon D; Kleyer A; Munoz L; Kretschmann S; Kharboutli S; Gary R; Reimann H; Rösler W; Uderhardt S; Bang H; Herrmann M; Ekici AB; Buettner C; Habenicht KM; Winkler TH; Krönke G; Schett G
    Nat Med; 2022 Oct; 28(10):2124-2132. PubMed ID: 36109639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing FLI1 levels in the MRL/lpr lupus mouse model impacts T cell function by modulating glycosphingolipid metabolism.
    Richard EM; Thiyagarajan T; Bunni MA; Basher F; Roddy PO; Siskind LJ; Nietert PJ; Nowling TK
    PLoS One; 2013; 8(9):e75175. PubMed ID: 24040398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of endogenous 4-1BB in the development of systemic lupus erythematosus.
    Vinay DS; Choi JH; Kim JD; Choi BK; Kwon BS
    Immunology; 2007 Nov; 122(3):394-400. PubMed ID: 17608689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus.
    Perper SJ; Westmoreland SV; Karman J; Twomey R; Seagal J; Wang R; McRae BL; Clarke SH
    J Immunol; 2019 Jul; 203(1):58-75. PubMed ID: 31109957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
    Pan Q; Xiao H; Shi L; He Y; Cai J; Wu J; Li A; Ye L; Yang C; Liu HF
    Front Immunol; 2020; 11():1047. PubMed ID: 32625200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice.
    Funes SC; Ríos M; Gómez-Santander F; Fernández-Fierro A; Altamirano-Lagos MJ; Rivera-Perez D; Pulgar-Sepúlveda R; Jara EL; Rebolledo-Zelada D; Villarroel A; Roa JC; Mackern-Oberti JP; Kalergis AM
    Immunology; 2019 Dec; 158(4):322-339. PubMed ID: 31509246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic effects of allogeneic mesenchymal stem cells on systemic lupus erythematosus.
    Liu F; Chen H; Chen T; Lau CS; Yu FX; Chen K; Chen HP; Pan RS; Chan GC; Zhang XY; Nie YJ
    Lupus; 2020 Jul; 29(8):872-883. PubMed ID: 32580680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 7 agonist imiquimod prevents the progression of SLE in MRL/lpr mice via inhibiting the differentiation of T follicular helper cells.
    Duan X; Shen C; Zhang X; Wu L; Chen J; Ma B; Wang Q; Sun P; Lan Y; Su C
    Int Immunopharmacol; 2020 Mar; 80():106239. PubMed ID: 32007709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Journal Club: Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus.
    Boulougoura A; Gendelman H; Surmachevska N; Kyttaris VC
    ACR Open Rheumatol; 2023 Nov; 5(11):624-628. PubMed ID: 37766597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
    Marinov AD; Wang H; Bastacky SI; van Puijenbroek E; Schindler T; Speziale D; Perro M; Klein C; Nickerson KM; Shlomchik MJ
    Arthritis Rheumatol; 2021 May; 73(5):826-836. PubMed ID: 33277983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
    Mihaylova N; Bradyanova S; Chipinski P; Chausheva S; Kyurkchiev D; Tchorbanov AI
    Scand J Immunol; 2020 Sep; 92(3):e12915. PubMed ID: 32533866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
    Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
    Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 attenuates behavioral deficits in a murine model of systemic lupus erythematosus.
    Shi D; Tian T; Yao S; Cao K; Zhu X; Zhang M; Wen S; Li L; Shi M; Zhou H
    Brain Behav Immun; 2018 May; 70():293-304. PubMed ID: 29548997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.